KRIBIOLISA™ Cemiplimab ELISA
Enzyme Immunoassay for the Quantitative Determination of Cemiplimab in human serum and plasma
Receive your quote directly from the manufacturer.
Introduction:
Cemiplimab is an immune checkpoint inhibitor monoclonal antibody blocking the PD-L1 pathway, approved in 2018 for the treatment of metastatic cutaneous squamous cell carcinoma. A fully human monoclonal antibody, it works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses It is also under investigation for myeloma, lung cancer and cervical cancer.
Intended Use:
The KRIBIOLISA™ Cemiplimab ELISA is used as an analytical tool for quantitative determination of Cemiplimab in human serum and plasma.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. PD-L1 recombinant protein is pre-coated onto microwells. Samples and standards are pipetted into microwells and Cemiplimab present in the sample are bound by the capture antibody. Then, an HRP (horseradish peroxidase) conjugated antiHuman IgG antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Cemiplimab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
